Sai Parenterals IPO 2026 – Date, Price Band, GMP, Review, Subscription & All Details
Latest Grey Market Premium & IPO Details
Sai Parenterals Limited IPO 2026 – Key Info & Highlights
Sai Parenterals Limited IPO opens 24-27 Mar 2026 with ₹285 Cr fresh issue. Face value ₹5/share, listing on 02 Apr 2026 on BSE & NSE. Invest in this pharma IPO for long-term growth.
📌 IPO Details
| Company Name | Sai Parenterals Limited IPO |
|---|---|
| Sector / Industry | Healthcare / Pharmaceuticals |
| IPO Open Date | 24-03-2026 |
| IPO Close Date | 27-03-2026 |
| Allotment Date | 30-03-2026 |
| Refund Date | 01-04-2026 |
| Share Credit Date | 01-04-2026 |
| Listing Date | 02-04-2026 |
| Price Band | ₹372 - ₹392 |
| Lot Size | 38 Shares |
| Min Investment | ₹14896 |
| Net Issue Size | ₹ 408.79 Cr |
| Fresh Issue | ₹285.00 Cr |
| OFS | ₹123.79 Cr |
| IPO Listing At | BSE NSE |
| DRHP | View DRHP |
| RHP | View RHP |
| Issue Type | Book Build Issue |
| Face Value | ₹5 Per Equity Share |
| Promoter Holding Pre IPO | 61.23 % |
* All Dates are provisional
Quota Allocation
| Category | Allocation (%) |
|---|---|
| Retail Investors | 35% |
| QIB (Qualified Institutional Buyers) | 50% |
| HNI (High Net Worth Individuals) | 15% |
📈 Grey Market Premium (GMP) Day-wise Trend
| GMP Date | GMP Price | Trend | Estimated Listing Price | Estimated Profit* | Last Updated |
|---|---|---|---|---|---|
| 02-04-2026 | ₹0.00 | - | ₹0.00 | ₹0.00 | 02-04-2026 10:00 |
| 01-04-2026 | ₹0.00 | - | ₹0.00 | ₹0.00 | 01-04-2026 23:20 |
| 31-03-2026 | ₹0.00 | - | ₹0.00 | ₹0.00 | 31-03-2026 23:20 |
📝 About Sai Parenterals Limited
Incorporated in 2001, Sai Parenteral's Limited is a diversified Indian pharmaceutical formulations company with deep expertise in research, development, and manufacturing of high-quality medicines for both domestic and international markets. The company operates across two main segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services.
Its product portfolio spans multiple therapeutic areas including cardiovascular health, neuropsychiatry, anti-diabetic care, respiratory health, antibiotics, gastroenterology, vitamins, minerals & supplements (VMS), analgesics, and dermatology. These products are manufactured in a variety of dosage forms such as injectables, tablets, capsules, liquid orals, and ointments, catering to diverse patient needs.
Sai Parenteral's serves a wide and diversified customer base, including central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists across India. The company expanded into exports in FY 2023, supplying to regulated and semi-regulated international markets including Australia, New Zealand, Southeast Asia, the Middle East, and Africa after acquiring internationally accredited manufacturing facilities.
The company owns and operates five manufacturing facilities in India: four in Hyderabad, Telangana — a GMP-compliant injectable unit, a WHO-GMP injectable unit, a TGA-Australia and PIC/S-accredited solid oral dosage unit, and a WHO-GMP cephalosporin facility. Its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified unit in Ongole, Andhra Pradesh, strengthening its manufacturing capabilities and ensuring compliance with global standards.
As of August 31, 2025, Sai Parenteral's employed 277 full-time professionals across manufacturing, R&D, and corporate functions. The company continues to invest in research and development, capacity expansion, and strategic acquisitions, including the Singapore-based subsidiary Sai Parenterals Pte Limited, to enhance its global footprint and long-term growth prospects.
Sai Parenterals Limited Revised Financials
Company Financial Report (₹ in Crores)
| Particulars | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 376.24 | 272.39 | 268.10 | 133.96 |
| Total Income | 89.43 | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 7.76 | 14.43 | 8.42 | 4.38 |
| EBITDA | 16.24 | 39.44 | 31.70 | 17.64 |
| Net Worth | 209.37 | 95.78 | 76.40 | 31.49 |
| Reserves and Surplus | 188.84 | 80.36 | 61.30 | 24.34 |
| Total Borrowing | 76.07 | 93.95 | 118.79 | 68.55 |
Note: All figures are in ₹ Crores. Data taken from company RHP / DRHP.
Sai Parenteral's IPO Objects of Issue
- Capacity Expansion & Facility Upgrade – ₹110.80 Cr will be used for expansion and upgradation of manufacturing facilities.
- New R&D Centre – ₹18.02 Cr will be used for establishment of a new research and development centre.
- Debt Repayment – ₹14.30 Cr will be used for repayment / prepayment of certain outstanding borrowings.
- Working Capital Requirements – ₹33.00 Cr will be used to meet working capital needs of the company.
- Investment in Subsidiary / Acquisition – ₹35.64 Cr will be invested in wholly owned subsidiary Sai Parenterals Pte Limited (Singapore) for acquisition of Noumed Pharmaceuticals Pty Limited (Australia).
- General Corporate Purposes – Remaining funds will be used for general corporate purposes.
Sai Parenteral's Limited Strengths
- Diversified Pharmaceutical Portfolio – The company manufactures a wide range of formulations including injectables, tablets, capsules, syrups and ointments for domestic and international markets.
- Modern Manufacturing Facilities – Sai Parenteral's has multiple manufacturing units with upgraded infrastructure to support capacity expansion and regulatory compliance.
- Strong Export Presence – The company exports pharmaceutical products to various countries including Australia, Asia and other international markets.
- Experienced Promoters and Management – The company is led by experienced promoters with long track record in the pharmaceutical and healthcare industry.
- Focus on Research & Development – The company is investing in a new R&D centre to develop new products and improve manufacturing efficiency.
- Growth Through Acquisition – The proposed investment in overseas subsidiary for acquisition of Noumed Pharmaceuticals will help expand global business operations.
Sai Parenteral's Limited Risk Factors
- Regional Concentration Risk – Most of the company’s manufacturing facilities are located in Hyderabad and Ongole. Any slowdown, natural disaster, political or economic disruption in these regions could negatively impact operations.
- Product Concentration Risk – A significant portion of revenue comes from injectable products. A decline in demand for these products could harm sales, profitability and cash flows.
- Regulatory and Compliance Risk – The pharmaceutical industry is heavily regulated, and failure to comply with existing or future regulatory requirements or inspections could lead to penalties, restrictions or reputation damage.
- Supply‑Chain Risk – The company relies on a range of suppliers for APIs, excipients and intermediates, without long‑term contracts. Any disruption or price volatility could materially impact operations.
- New Product Development Risk – Growth depends on timely development and commercialisation of new products. Delays or failures would adversely affect financial performance.
- Customer Concentration Risk – A significant share of revenue comes from a limited group of customers. Loss of key customers or deterioration in their financial condition could materially affect the company’s results.
- International Operations Risk – Overseas business exposes the company to legal, economic, tax and management risks in foreign markets.
- Expansion Disruption Risk – Planned capacity expansion or upgrade may require temporary shutdown of manufacturing units, potentially disrupting production and sales during the transition.
Company Information
Founded in: 2001
Address: Plot No-39, 4th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, Hyderabad – 500032, Telangana, India
Website: www.saiparenterals.com
Phone: +91 79979 91301
Email: cs@saiparenterals.com
IPO Quick Info
24 Mar 2026
27 Mar 2026
Upcoming
Lead Manager(s)
- Arihant Capital Markets Ltd.
Related IPOs
- Bagmane REIT
- Recode Studios
- OnEMI Technology
- Value 360 Communications
- Amba Auto Sales & Services
- Adisoft Technologies
- Leapfrog Engineering
- Citius Transnet InvIT
- Mehul Telecom
- Om Power Transmission
- Propshare Celestia
- Safety Controls
- Emiac Technologies
- Vivid Electromech
- Highness Microelectronics
- Powerica Limited
- Speciality Medicines
- Tipco Engineering
- Amir Chand Jagdish Kumar
Frequently Asked Questions
Sai Parenteral operates primarily in the pharmaceutical and healthcare industry, focusing on formulations, manufacturing, and CDMO services for domestic and international markets.